NuCana Stock (NASDAQ:NCNA)


OwnershipFinancialsChart

Previous Close

$1.44

52W Range

$1.27 - $19.40

50D Avg

$2.20

200D Avg

$4.33

Market Cap

$3.09M

Avg Vol (3M)

$1.40M

Beta

1.04

Div Yield

-

NCNA Company Profile


NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

GB

Employees

25

IPO Date

Sep 28, 2017

Website

NCNA Performance


NCNA Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income£-32.78M£-39.12M£-47.91M
Net Income£-27.63M£-32.02M£-40.53M
EBITDA£-28.89M£-47.58M£-41.88M
Basic EPS£-0.53£-0.62£-0.79
Diluted EPS£-0.53£-0.61£-0.78

Fiscal year ends in Dec 23 | Currency in GBP

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
APLTApplied Therapeutics, Inc.
VIRIVirios Therapeutics, Inc.
MREOMereo BioPharma Group plc
RANIRani Therapeutics Holdings, Inc.
DAWNDay One Biopharmaceuticals, Inc.
TNYATenaya Therapeutics, Inc.
SLNSilence Therapeutics plc
CTMXCytomX Therapeutics, Inc.
CRVSCorvus Pharmaceuticals, Inc.
ALXOALX Oncology Holdings Inc.
INZYInozyme Pharma, Inc.
EFTReFFECTOR Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.
VINCVincerx Pharma, Inc.
CDTXCidara Therapeutics, Inc.
ZURAZura Bio Limited